3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
3
Skin Neoplasms
2
Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Skin Diseases
1
Rectal Neoplasms
1
Rectal Diseases
1
Neoplasm Metastasis
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Diseases
1
Biliary Tract Neoplasms
1
Interventions
Leucovorin
22
Fluorouracil
22
Paclitaxel
21
Gemcitabine
21
Docetaxel
21
Capecitabine
21
Irinotecan
16
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
encorafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA